| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 19,550 | 21,760 | 40,800 | 46,720 | 44,970 |
| Sales Growth | -10.16% | -46.67% | -12.67% | +3.89% | +20.85% |
| Net Income | -34,690 | -33,460 | -26,030 | -34,070 | -26,940 |
| Net Income Growth | -3.68% | -28.54% | +23.60% | -26.47% | +41.08% |
Standard Biotools Inc (LAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Standard BioTools Inc. is a solution provider in health and disease using its proprietary mass cytometry and microfluidics technologies. It serves academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories. Standard BioTools Inc., formerly known as Fluidigm Corporation, is based in SOUTH SAN FRANCISCO, Calif.
Fiscal Year End Date: 12/31